Full name

A Phase 2a Randomized, Observer-blind, Dose-finding Study to Evaluate the Immunogenicity and Safety of mRNA-based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age and Older

NCT Number
NCT06431607
Geography
US
Locations

United States

Primary Endpoints
  • Geometric mean titer (GMT) of antigen 1 antibody. At Day 29
  • Geometric mean increase (GMI) of Antigen 1 antibody titer. From Day 1 to Day 29
  • Percentage of participants with antigen 1 seroconversion (SCR). From Day 1 to Day 29
  • Percentage of participants with antigen 1 titer greater than or equal to (>) the cut off value at Day 1
  • Percentage of participants with antigen 1 titer > the cut off value at Day 29
External Link
https://clinicaltrials.gov/study/NCT06431607
Order
2
Disease
Flu Vaccine
Menu title
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
Version
ATS 2025
Phase
2a
Status
Active, not recruiting